Category: Federal Forum Posters
Purpose: Benzodiazepines are first line agents in the management of alcohol withdrawal syndrome (AWS). In the geriatric population, benzodiazepines can be associated with an increased risk of delirium and falls. Gabapentin has been shown to help reduce the incidence of seizures and alcohol cravings. Currently, there are no data regarding gabapentin’s effect on total daily benzodiazepine use when used as an adjunctive therapy in AWS. The purpose of this study is to evaluate whether combination therapy with gabapentin versus benzodiazepine monotherapy may decrease the total daily dose of benzodiazepines used for veterans receiving care for AWS.
Methods: This study, a retrospective chart review, was recently submitted to the Institutional Review Board for approval. To be included in this study, subjects will be aged 18-79, will have been admitted to the Southern Arizona Veterans Affairs Health Care System (SAVAHCS) between 12/01/2017 and 7/31/2018 for AWS, and received either benzodiazepine therapy alone or a combination of benzodiazepine and gabapentin therapy. Baseline demographic information (e.g. gender, age, blood alcohol level upon admission) will be collected as well as information regarding length of stay, total daily benzodiazepine dosage, and daily Clinical Institute Withdrawal Assessment of Alcohol – Revised (CIWA-Ar) score. The primary outcome will be to evaluate the total daily dose of benzodiazepines utilized in AWS for patients receiving benzodiazepines alone compared to those receiving benzodiazepines in combination with gabapentin. Secondary outcomes will include length of stay, total benzodiazepine use during admission, re-admission rates for AWS, delirium, and escalation of care for patients on combination therapy versus monotherapy.
Results: not applicable
Conclusion: not applicable
Kimberly Sassenrath– Pharmacy Resident, Southern Arizona VA Health Care System, Tucson, AZ